You can buy or sell AMRX and other stocks, options, ETFs, and crypto commission-free!
Amneal Pharmaceuticals, Inc. Class A Common Stock, also called Amneal Pharmaceuticals, is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. Read More It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
Bridgewater, New Jersey
52 Week High
52 Week Low
The Qualcomm Sell-Down Is Overdone
Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s. Some of the reports’ issuers have provided, or hope to provide, investment-banking or other services to the companies being analyzed. Qualcomm QCOM-Nasdaq Buy Price $76.62 on May 20 by Canaccord Genuity Following the U.S. Commerce Department’s addition of Huawei and its ...
Seeking AlphaMay 9
Amneal Pharmaceuticals' CEO Rob Stewart on Q1 2019 Results - Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Mark Donohue – Vice President of Investor Relations and Corporate Communications Rob Stewart – President and Chief Executive Officer Todd Branning – Chief Financial Officer Joe Todisco – Senior Vice President of Specialty Commercial Conference Call Participants Jennifer Kim – Cantor Fitzgerald Gary Nachman – BMO Capital Markets David Amsellem – Piper Jaffray Eason Lee – SVB Leerink...
Why Amneal Pharmaceuticals Stock Is Cratering Today
What happened Shares of the generic and specialty drug makerAmneal Pharmaceuticals (NYSE: AMRX) fell by more than 19% in early-morning trading today on heavy volume. The culprit? Amneal released its first-quarter earnings report before the opening bell this morning, and it apparently didn't go over well with investors. Although the company beat consensus on revenue by a modest $7.4 million (approximately 1.7% higher than expected), Amneal also posted a hefty net loss of $125 million for the quarter. Imag...
Available Aug 8, Pre-Market